retatrutide triple agonist glp-1 gip glucagon is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials mg:50mg form:Lyophilised powder Some of my patients

retatrutide triple agonist glp-1 gip glucagon is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials mg:50mg form:Lyophilised powder Some of my patients

Some of my patients spent years fighting disordered eating and now they're asking me about GLP-1s. That history doesn't disappear, and it's something I haven't heard much about. I wrote about this

Patients should select products from reputable manufacturers that undergo third-party testing, such as those verified by USP (United States Pharmacopeia) or NSF International

form:Lyophilised powder

mg:50mg

Cardiovascular outcome trials show that treatment with long-acting GLP-1 medicines such as liraglutide, dulaglutide, and semaglutide reduces cardiovascular events in people living with T2D and with semaglutide also in people living with obesity (60–62)